This New Jersey bill requires health insurance plans to cover colorectal cancer screenings for all covered individuals aged 33 and older, as well as for those under 33 if a physician deems the screening medically necessary. The law mandates that these screenings follow the most recent guidelines from the United States Preventive Services Task Force and must be provided without any deductibles, copayments, or other cost-sharing fees if a follow-up colonoscopy is needed after a positive initial test. By amending existing statutes for hospital, medical, and health service corporations, the legislation ensures that these specific cancer prevention services are treated with the same coverage standards as other medical conditions.
This New Jersey bill mandates that health insurance plans cover early-stage kidney disease screening without charging patients any deductibles, copayments, or coinsurance. The law specifically requires coverage for blood tests measuring glomerular filtration rate and urine tests checking albumin-creatinine ratios when a physician deems them medically necessary. Insurance providers must treat these screenings with the same benefits as other medical conditions, provided the patient meets clinical guidelines set by the National Kidney Foundation. The policy applies to various types of hospital and medical service contracts issued or renewed in the state after the act takes effect.
This bill requires health insurance plans in New Jersey to cover routine HIV testing for patients receiving care in primary care settings, emergency departments, and other appropriate health facilities. Under the new rules, HIV testing will be performed automatically unless a patient explicitly opts out, provided they have already given general consent for their medical visit. The legislation also mandates that insurance contracts cannot be issued or renewed without including these testing benefits, ensuring coverage is treated like any other medical condition.
This bill allows chambers of commerce, trade associations, and nonprofit business coalitions in New Jersey to create their own group health insurance plans for their member businesses. To encourage participation, the legislation provides a state tax credit of up to $1,000 per employee annually for businesses enrolled in these new plans, with a maximum annual limit of $20,000 per taxpayer. Additionally, the bill requires the state to launch a public awareness campaign funded by at least $500,000 to inform businesses about these coverage options and offers grants to help organizations cover the administrative costs of managing the plans.
This New Jersey bill mandates that health insurance plans and Medicaid cover medically necessary tests and FDA-approved treatments designed to slow the progression of Alzheimer's disease and related disorders. The law applies to hospital service, medical service, and health service corporation contracts, as well as individual and group health insurance policies issued or renewed in the state. A key provision ensures that these specific Alzheimer's treatments are not subject to step therapy requirements, meaning patients can access them without needing to try other medications first. Additionally, the coverage must be provided at the same level as benefits for other medical conditions.
This New Jersey bill mandates that all health insurance plans cover the cost of genetic testing for individuals diagnosed with pancreatic cancer. The law applies to hospital service corporations, medical service corporations, health service corporations, and individual policies issued or renewed in the state after the effective date. Under the new rule, insurers must treat these genetic tests the same as any other medical condition, ensuring they are covered without additional restrictions. The legislation defines genetic testing broadly to include tests that analyze DNA, RNA, chromosomes, or proteins to identify mutations that guide treatment and monitoring.
This New Jersey bill mandates that all health insurance plans and Medicaid programs cover medically necessary tests and FDA-approved treatments designed to slow the progression of Alzheimer's disease and related disorders. The law requires these benefits to be treated the same as coverage for other conditions, specifically exempting them from step therapy requirements that often delay access to medications. These provisions apply to hospital, medical, and health service corporation contracts, as well as individual and group health insurance policies issued or renewed in the state. The coverage must be determined by a physician and align with the official labeling approved by the U.S. Food and Drug Administration.
This bill mandates that New Jersey's state health insurance programs, including SHBP, SEHBP, and NJ FamilyCare, must cover education services for patients with kidney disease who need dialysis or a transplant. The legislation requires the Department of Health to create specific guidelines for these services, which involve verbal counseling on managing related health conditions, preventing complications, and understanding treatment options like different types of dialysis or transplantation. Under the plan, patients would receive this information before their appointments to help them actively participate in choosing their treatment path. The coverage for the NJ FamilyCare program is specifically noted as dependent on receiving approval from the federal government.
This bill requires health insurance carriers and Medicaid programs in New Jersey to pay licensed clinical laboratories for services regardless of whether those labs participate in a managed care plan. It mandates that non-participating labs receive reimbursement at the same rate as participating ones, while still allowing insurers to review services for medical necessity. Additionally, the legislation prohibits state Medicaid officials from forcing labs to join managed care networks as a condition for receiving payment or transitioning from fee-for-service to managed care systems.
This bill requires workers' compensation, private passenger automobile insurance, and health insurance plans in New Jersey to cover the costs of medical cannabis for qualifying patients authorized under state law. The legislation applies to employees injured on the job, individuals involved in auto accidents, and health plan members who meet medical cannabis patient criteria. Coverage includes direct payment to dispensaries or reimbursement to patients if direct payment isn't feasible, with an exception if federal authorities intervene to enforce the Controlled Substances Act. The bill also includes a finding that medical cannabis has therapeutic value for conditions like pain, nausea, and multiple sclerosis.
